Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells

Chimeric antigen receptor (CAR) T cell technology has enabled successfully novel concepts to treat cancer patients, with substantial remission rates in lymphoid malignancies. This cell therapy is based on autologous T lymphocytes that are genetically modified to express a CAR that recognizes tumor-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosti, Laura, Langner, Lukas M., Chmielewski, Kay O., Arbuthnot, Patrick, Alzubi, Jamal, Cathomen, Toni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455323/
https://www.ncbi.nlm.nih.gov/pubmed/33526841
http://dx.doi.org/10.1038/s41434-021-00220-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455323/
https://www.ncbi.nlm.nih.gov/pubmed/33526841
http://dx.doi.org/10.1038/s41434-021-00220-6

Ejemplares similares